These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25569441)

  • 1. Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.
    Pashayan N; Duffy SW; Neal DE; Hamdy FC; Donovan JL; Martin RM; Harrington P; Benlloch S; Amin Al Olama A; Shah M; Kote-Jarai Z; Easton DF; Eeles R; Pharoah PD
    Genet Med; 2015 Oct; 17(10):789-95. PubMed ID: 25569441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.
    Pashayan N; Pharoah PD; Schleutker J; Talala K; Tammela TLj; Määttänen L; Harrington P; Tyrer J; Eeles R; Duffy SW; Auvinen A
    Br J Cancer; 2015 Sep; 113(7):1086-93. PubMed ID: 26291059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.
    Pashayan N; Duffy SW; Pharoah P; Greenberg D; Donovan J; Martin RM; Hamdy F; Neal DE
    Br J Cancer; 2009 Apr; 100(7):1198-204. PubMed ID: 19293796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
    Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
    J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized estimates of overdiagnosis in screen-detected prostate cancer.
    Gulati R; Inoue LY; Gore JL; Katcher J; Etzioni R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt367. PubMed ID: 24399850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.
    Pathirana T; Hayen A; Doust J; Glasziou P; Bell K
    BMJ Open; 2019 Mar; 9(3):e022457. PubMed ID: 30858156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
    Getaneh AM; Heijnsdijk EAM; Roobol MJ; de Koning HJ
    Cancer Med; 2020 Oct; 9(20):7742-7750. PubMed ID: 32813910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
    Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
    BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer in the US? Reduce the harms and keep the benefit.
    de Carvalho TM; Heijnsdijk EA; de Koning HJ
    Int J Cancer; 2015 Apr; 136(7):1600-7. PubMed ID: 25123412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
    Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
    J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    Nyame YA; Gulati R; Heijnsdijk EAM; Tsodikov A; Mariotto AB; Gore JL; Etzioni R
    J Natl Cancer Inst; 2021 Oct; 113(10):1336-1342. PubMed ID: 33963850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model.
    Nordström T; Grönberg H; Adolfsson J; Egevad L; Aly M; Eklund M
    Eur Urol Focus; 2018 Apr; 4(3):385-387. PubMed ID: 28753831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study.
    Zappa M; Ciatto S; Bonardi R; Mazzotta A
    Ann Oncol; 1998 Dec; 9(12):1297-300. PubMed ID: 9932159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.
    Etzioni R; Gulati R; Mallinger L; Mandelblatt J
    Ann Intern Med; 2013 Jun; 158(11):831-8. PubMed ID: 23732716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study.
    Kirkegaard P; Edwards A; Nielsen TLO; Ørntoft TF; Sørensen KD; Borre M; Bro F
    BMC Fam Pract; 2018 Feb; 19(1):32. PubMed ID: 29454309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.